Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

ABSTRACT: Background: Historically, the standard of care for patients with unresectable, Stage III non–small cell lung cancer had been concurrent chemoradiotherapy. However, outcomes had been poor, with approximately 15% to 32% of patients alive at 5 years. In the placebo-controlled Phase III A PAC...

Full description

Bibliographic Details
Main Authors: Mario Ouwens, PhD, Annie Darilay, PhD, Yiduo Zhang, PhD, Pralay Mukhopadhyay, PhD, Helen Mann, MSc, James Ryan, MSc, Phillip A. Dennis, MD
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Current Therapeutic Research
Subjects:
Durvalumab
Modified 2-stage method
Overall survival
PACIFIC
Rank Preserving Structural Failure Time Model
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X21000187

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X21000187

Similar Items